Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation
Thank you for contacting us
And that's where today's consultation became interesting
MSQOL-54, Multiple Sclerosis Quality of Life-54
US$ 25.36
US$ 25.79
US$ 21.39
US$ 25.16
